Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials
Standard
Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials : is there a selection bias? / Beinhardt, Sandra; Staettermayer, Albert F; Rutter, Karoline; Maresch, Judith; Scherzer, Thomas M; Steindl-Munda, Petra; Hofer, Harald; Ferenci, Peter.
In: HEPATOLOGY, Vol. 55, No. 1, 01.01.2012, p. 30-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials
T2 - is there a selection bias?
AU - Beinhardt, Sandra
AU - Staettermayer, Albert F
AU - Rutter, Karoline
AU - Maresch, Judith
AU - Scherzer, Thomas M
AU - Steindl-Munda, Petra
AU - Hofer, Harald
AU - Ferenci, Peter
N1 - Copyright © 2011 American Association for the Study of Liver Diseases.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Currently, direct-acting antiviral agents (DAAs) are evaluated in clinical trials. The aim of this study was to compare baseline characteristics and sustained virologic response (SVR) rates in patients included in clinical trials to those receiving SOC. Medical records of all 503 treatment-naïve patients with CHC, genotype (GT) 1, referred over a 4-year period (January 2006-December 2009) were reviewed. Only 310 of 503 (62%) patients received antiviral therapy, 141 were enrolled in randomized, controlled trials ("study patients"; 101 in DAA studies), and 169 received SOC. At baseline, viral load and platelet count were higher and bilirubin was lower in study patients than in SOC patients. History of psychiatric disorders was more common in SOC patients (43 [25%] versus study patients with 18 [13%]; P < 0.01). Liver biopsy was obtained in 98% of study patients, but only in 59% of SOC patients. Twenty-nine (21%) and 40 (40%) study and SOC patients, respectively, had advanced fibrosis (F3/4; P = 0.001). By intent-to-treat analysis, SVR rates were higher in DAAs (64%; 95% confidence interval [CI]: 53.4-74.4) than in SOC patients (46%; 95% CI: 37.9-53.7; P < 0.01), but not different when calculated on a treated-per-protocol (TPP) basis. Interleukin (IL)28B GT was equally distributed in both cohorts. By chance, more patients treated with IFN/RBV had rs12979860 C/C-GT (up to 44%) than DAA-treated patients. If analyzed according to the IL28B polymorphism, TPP SVR rates did not reach statistically significant differences among study and SOC patients.CONCLUSIONS: Baseline characteristics slightly favored study patients, but IL28B GT and treatment adherence were the most important factors determining outcome. Thus, the applicability of the results of controlled studies has to be tested in a "real-world" setting.
AB - UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Currently, direct-acting antiviral agents (DAAs) are evaluated in clinical trials. The aim of this study was to compare baseline characteristics and sustained virologic response (SVR) rates in patients included in clinical trials to those receiving SOC. Medical records of all 503 treatment-naïve patients with CHC, genotype (GT) 1, referred over a 4-year period (January 2006-December 2009) were reviewed. Only 310 of 503 (62%) patients received antiviral therapy, 141 were enrolled in randomized, controlled trials ("study patients"; 101 in DAA studies), and 169 received SOC. At baseline, viral load and platelet count were higher and bilirubin was lower in study patients than in SOC patients. History of psychiatric disorders was more common in SOC patients (43 [25%] versus study patients with 18 [13%]; P < 0.01). Liver biopsy was obtained in 98% of study patients, but only in 59% of SOC patients. Twenty-nine (21%) and 40 (40%) study and SOC patients, respectively, had advanced fibrosis (F3/4; P = 0.001). By intent-to-treat analysis, SVR rates were higher in DAAs (64%; 95% confidence interval [CI]: 53.4-74.4) than in SOC patients (46%; 95% CI: 37.9-53.7; P < 0.01), but not different when calculated on a treated-per-protocol (TPP) basis. Interleukin (IL)28B GT was equally distributed in both cohorts. By chance, more patients treated with IFN/RBV had rs12979860 C/C-GT (up to 44%) than DAA-treated patients. If analyzed according to the IL28B polymorphism, TPP SVR rates did not reach statistically significant differences among study and SOC patients.CONCLUSIONS: Baseline characteristics slightly favored study patients, but IL28B GT and treatment adherence were the most important factors determining outcome. Thus, the applicability of the results of controlled studies has to be tested in a "real-world" setting.
KW - Academic Medical Centers
KW - Adult
KW - Antiviral Agents
KW - Europe
KW - Female
KW - Genotype
KW - Hepacivirus
KW - Hepatitis C, Chronic
KW - Humans
KW - Interleukins
KW - Male
KW - Middle Aged
KW - Patient Selection
KW - Polymorphism, Genetic
KW - Prospective Studies
KW - Randomized Controlled Trials as Topic
KW - Retrospective Studies
KW - Selection Bias
KW - Treatment Outcome
U2 - 10.1002/hep.24671
DO - 10.1002/hep.24671
M3 - SCORING: Journal article
C2 - 21932410
VL - 55
SP - 30
EP - 38
JO - HEPATOLOGY
JF - HEPATOLOGY
SN - 0270-9139
IS - 1
ER -